Second Sight Medical (EYES) Picks Up Chatter Ahead of CNBC Coverage

Second Sight Medical (EYES) Sees Profit Taking after 162% Post-IPO Surge

This week's hot IPO for Second Sight Medical (NASDAQ: EYES) is giving some back today. After gaining 162% in it fist two days of trading, shares are down 9.5% to $21.35 today. The IPO priced at $9.

Second Sight develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients

Second Sight Medical (EYES) Momentum Continues Following Robust IPO

Second Sight Medical (NASDAQ: EYES) is showing early gains Thursday following the company's strong debut on yesterday's session.

Wednesday, Second Sight opened for trading at $17 after pricing 3.5 million common shares at $9 apiece. Overall, the stock close 122 percent higher to $19.97.

Ahead of the bell, Second Sight is up an additional 15 percent.

Second Sight Medical (EYES) IPO Immediately Halted on Opening Surge

Today's IPO for Second Sight Medical (NASDAQ: EYES) was immediately halted upon opening for trading at $17 versus the IPO price of $9.

Second Sight Medical (EYES) IPO Opens Sharply Higher

Today's IPO for Second Sight Medical (NASDAQ: EYES) opened for trading at $17 after pricing 3,500,000 shares of common stock at a price of $9.00 per share, in-line with the expected pricing.

MDB Capital Group, LLC served as the sole underwriter in connection with the... More

Second Sight Medical Products (EYES) Prices 3.5M Common IPO at $9/Share

Second Sight Medical Products, Inc. (Nasdaq: EYES) announced the pricing of its initial public offering of 3,500,000 shares of common stock, at a price of $9.00 per share. Second Sight develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. Its current product, the Argus® II System, which treats outer retinal degenerations such as retinitis... More